Pages that link to "Q24608039"
Jump to navigation
Jump to search
The following pages link to Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis (Q24608039):
Displaying 50 items.
- Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody (Q21132534) (← links)
- Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme (Q21135142) (← links)
- Cutting off cancer's supply lines (Q22251124) (← links)
- Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale (Q22252358) (← links)
- Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer (Q24202199) (← links)
- VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex (Q24293027) (← links)
- Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage (Q24295214) (← links)
- Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma (Q24295370) (← links)
- CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo (Q24296427) (← links)
- Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression (Q24595357) (← links)
- A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers (Q24595527) (← links)
- Guidance molecules in lung cancer (Q24598659) (← links)
- Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition (Q24616631) (← links)
- Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma (Q24632791) (← links)
- Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin (Q24635068) (← links)
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 (Q24657145) (← links)
- Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis (Q26740812) (← links)
- Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy (Q26741450) (← links)
- Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics (Q26746067) (← links)
- Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents (Q26747054) (← links)
- Tumor refractoriness to anti-VEGF therapy (Q26747678) (← links)
- Epithelial-to-endothelial transition and cancer stem cells: two cornerstones of vasculogenic mimicry in malignant tumors (Q26749164) (← links)
- Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction (Q26749333) (← links)
- Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next? (Q26752752) (← links)
- Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality? (Q26764984) (← links)
- Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets (Q26765758) (← links)
- Targeting Notch to overcome radiation resistance (Q26771701) (← links)
- Sequence of treatment in locally advanced and metastatic renal cell carcinoma (Q26773653) (← links)
- Profile of nintedanib in the treatment of solid tumors: the evidence to date (Q26775134) (← links)
- c-Met as a Target for Personalized Therapy (Q26775483) (← links)
- Anti-angiogenic alternatives to VEGF blockade (Q26775947) (← links)
- Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1 (Q26778957) (← links)
- The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer (Q26779248) (← links)
- Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization (Q26781833) (← links)
- Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution (Q26796955) (← links)
- Optimal combination of antiangiogenic therapy for hepatocellular carcinoma (Q26799458) (← links)
- The Contribution of Angiogenesis to the Process of Metastasis (Q26801841) (← links)
- The evolution of endothelial regulatory paradigms in cancer biology and vascular repair (Q26822678) (← links)
- Hypoxic signaling during tissue repair and regenerative medicine (Q26824402) (← links)
- Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme (Q26824557) (← links)
- Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials (Q26824909) (← links)
- Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma (Q26826862) (← links)
- From sprouting angiogenesis to erythrocytes generation by cancer stem cells: evolving concepts in tumor microcirculation (Q26827148) (← links)
- Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads (Q26830075) (← links)
- NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age (Q26830388) (← links)
- Intertwined regulation of angiogenesis and immunity by myeloid cells (Q26830418) (← links)
- Twisted tango: brain tumor neurovascular interactions (Q26849613) (← links)
- The microenvironment in breast cancer progression: biology and implications for treatment (Q26851314) (← links)
- Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment (Q26852398) (← links)
- Notch: a key regulator of tumor angiogenesis and metastasis (Q26858778) (← links)